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Abstract 
Background: There is an unmet need for more efficient patient stratification for receiving trastuzumab in the meta-
static breast cancer (mBC) setting, since only part of such patients benefit from the addition of this agent to chemo-
therapy. The aim of this study was to investigate the prognostic value of biomarkers including MYC and MET in mBC 
patients treated with trastuzumab-based regimens.
Methods: mBC patients, locally tested as HER2-positive, treated with trastuzumab and chemotherapy between 1998 
and 2010 were evaluated. Paraffin tumors (n = 229) were retrospectively centrally assessed by immunohistochemistry 
(IHC) for HER2, ER, PgR and Ki67; fluorescence in situ hybridization (FISH) for HER2, TOP2A and centromere (CEN) 17, 
MYC and CEN8, MET and CEN7; qPCR for MYC, MET copy number (CN); and, for PI3K activation (PIK3CA mutations; 
PTEN and phospho-mTOR protein expression). Increased CEN CN was assessed based on normal cut-offs. Time to 
progression (TTP) and survival were evaluated from the initiation of trastuzumab as first line treatment.
Results: Among all tumors, 90 were HER2-negative upon central testing (ambiguous HER2) and the rest were true 
HER2-positive. Further, 156 patients presented with mBC upon relapse of pre-treated disease (R-mBC) and 65 were 
diagnosed at stage IV (de novo mBC). Concordance between FISH and qPCR on gene CN status was fair for MYC 
(Kappa = 0.458) and absent for MET. The presence of MYC CN gain with qPCR and the absence of PI3K activation were 
infrequent events (7 and 8 % of evaluable tumors, respectively), while 41 % of tumors had increased CEN CN in one or 
more chromosomes, indicative of chromosomal instability. The most consistent finding in the entire cohort and in the 
above patient subgroups with respect to outcome was the unfavourable effect of MYC CN gain, which was retained 
upon multivariable analysis (e.g., survival in the entire cohort, HR 6.02; 95 % CI 2.67–13.6; p < 0.001). Further unfavour-
able prognosticators were increased CEN CN in one chromosome in R-mBC but not in de novo mBC (multivariable 
interaction p = 0.048), PI3K activation in R-mBC (multivariable p = 0.004) and increased Ki67 for patient TTP.
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Background
The proto-oncogene HER2 (ERBB2) is amplified in 
approximately 20  % of breast cancers and is associ-
ated with a number of adverse prognostic factors, such 
as increased proliferative indices [1, 2], metastasis and 
recurrence. Trastuzumab, the first of a series of anti-
HER2 agents, is a recombinant monoclonal antibody 
directed against the extracellular domain of the HER2 
protein and has become the standard of care for patients 
with HER2-positive breast cancer, since it prolongs pro-
gression-free and overall survival in the adjuvant or met-
astatic settings [3, 4]. However, there is a large proportion 
of HER2-positive patients that do not gain clinical benefit 
from such agents either as single agents or in combina-
tion with chemotherapy [5], many of them presenting 
with up-front resistance [1, 6, 7]. Efforts are still ongo-
ing for refining treatment strategies by incorporating 
different anti-HER2 agents, thus sparing both potential 
unnecessary toxicities associated with therapy and also 
potential treatment failures resulting from inappropriate 
treatment schedules or from treatments that negatively 
impinge upon survival [8]. For the identification of more 
efficient prognostic biomarkers in patients treated with 
trastuzumab, the effects of genes and proteins implicated 
in the HER2 signalling pathway(s) are usually studied on 
patient tumor material.
By-pass of signalling or de-novo resistance to targeted 
agents are important mechanisms that cancers utilize 
to fight our therapeutic armamentarium. Elucidation of 
de-novo or acquired mechanisms of resistance to sev-
eral agents requires the same diligence for finding the 
targetable biomarker, as we further understand the het-
erogeneity of tumors. HER2 is a member of the HER 
tyrosine kinase family expressed in virtually all cancer 
types. Interaction of the HER-signalling pathway(s) with 
the PI3K/AKT signalling pathway that plays a role in cell 
growth, metabolism, cell survival and oncogenesis [9, 10] 
is well acknowledged. MET over-expression or gene gain 
on chromosome 7q31 has been reported in a variety of 
tumors including breast cancers, correlating with poor 
prognosis [11]. MET activates many of the downstream 
pathway members of HER2, including PI3K, AKT, PLCg 
and RAS-MAPK, and as such may act as a negative indi-
cator of trastuzumab efficacy.
MYC, a proto-oncogene located at 8q24.1, plays a cen-
tral role in proliferation and malignant transformation. 
The gene encodes 3 different transcription factors that 
play a role in normal cellular function, replication, pro-
liferation and apoptosis [12, 13]. Aberrations in MYC 
have been reported to play a key role as potent activa-
tors of malignant transformation and progression in 
several types of human malignancies [14, 15]. In breast 
cancer its amplification and/or overexpression is consist-
ently observed in more aggressive ER-negative disease, 
correlating with poor prognosis and distant metastases 
[16–18]. Depending on the technique used [19], several 
inconsistent correlations with clinicopathological factors 
have been reported, as has the frequency of overexpres-
sion ranging from 1–95 %. FISH has been considered to 
be the optimal method for assessing MYC gene status, as 
it includes a centromeric probe that appears necessary to 
differentiate between polysomy and gene amplification 
[20].
In the present retrospective translational research 
study, we sought to investigate the effect of MET and 
MYC status on the outcome of trastuzumab treated 
patients with mBC in a cohort previously analyzed by 
our group for PIK3CA and PTEN, as well as HER2 and 
TOP2A status [21, 22]. Herein, MET and MYC were 
investigated with four different methods at the gene 
(chromosome), mRNA and protein levels. In addition, 
the number of centromere copies for the three chromo-
somes harbouring the genes studied (chr17, chr7, and 
chr8) was also analyzed. Finally, because of the central 
role of the PI3K pathways in the maintenance of HER2-
positive tumors, MET and MYC status were assessed in 
combination with PI3K/AKT/mTOR parameters.
Methods
Patients and tumor tissue material
The study was performed on formalin-fixed paraffin-
embedded (FFPE) tumor tissue material collected 
from patients with mBC that were treated with trastu-
zumab-based combinations between December 1998 
and January 2010 in HeCOG affiliated clinical centers, 
as described previously [21, 22]. Eligibility criteria for 
case analysis in the present study were, histologically 
confirmed mBC; adequacy of clinical data on patient’s 
history, demographics, tumor characteristics, treat-
ment details (drug dosage, schedule of administration, 
adverse events) and clinical outcome (patients lost to 
follow-up were excluded); availability of adequate FFPE 
Conclusions: MYC gene copies, centromere status and PI3K activation may adversely impact trastuzumab treated 
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tumor tissue for biological marker evaluation; trastu-
zumab-based treatment for metastatic disease; and, no 
adjuvant treatment with trastuzumab. The translational 
research protocol was approved by the Bioethics Com-
mittee of the Aristotle University of Thessaloniki School 
of Medicine (#4283; January 14, 2008) under the general 
title ‘‘Investigation of major mechanisms of resistance 
to treatment with trastuzumab in patients with meta-
static breast cancer’’. All patients included in the study 
after 2005, provided written informed consent for the 
provision of biological material for future research stud-
ies, before receiving any treatment. Waiver of consent 
was obtained from the Bioethics Committee for patients 
included in the study before 2005. Patients presented 
with mBC either upon relapse of previously treated dis-
ease (R-mBC) or de novo, without previous history of 
breast cancer. However, tissue material from the primary 
tumors was examined in most cases.
FFPE tissue processing
Patients had received trastuzumab based on HER2 
assessment in local pathology laboratories. However, 
because of the broad period of patient recruitment dur-
ing which ER, PgR and HER2 guidelines for breast tumor 
typing and patient stratification for trastuzumab treat-
ment were repeatedly modified, all tumors were re-
evaluated centrally for these basic breast cancer typing 
parameters, in the laboratory of Molecular Oncology. ER, 
PgR and HER2 were evaluated according to ASCO/CAP 
guidelines as previously published [21, 22].
In total, 229 cases meeting the above eligibility criteria 
for patients and tissues were examined. Corresponding 
tumors were histologically evaluated on hematoxylin & 
eosin (H&E) sections for tumor presence and marked for 
the most tumor dense areas. Tumor cell content (TCC) 
was assessed as the ratio of cancer cells vs. non-cancer 
cells in these areas, which were used for manual macro-
dissection for DNA/RNA extraction and, upon a second 
H&E evaluation, for obtaining cores for tissue microarray 
(TMA) construction, in this order. Manual macrodissec-
tion was performed on 10 micron thick unstained sec-
tions and processed for dual nucleic acid extraction with 
silica-coated magnetic beads (Versant Tissue Preparation 
Reagents, Siemens Healthcare Diagnostics, Tarrytown, 
NY, USA), according to the manufacturer’s instructions. 
Based on the abundance of tumor tissue on blocks and 
the availability of thick sections, extracts were divided 
into two aliquots for storage at −20 °C until use. DNase 
I was added to one aliquot per sample for removing DNA 
and ensuring the presence of pure RNA for gene expres-
sion analyses. TMAs were used for all in  situ methods, 
i.e., immunohistochemistry (IHC) and fluorescent in situ 
hybridization (FISH). These methods were performed on 
3 and 5 micron thick TMA sections, respectively. Seven-
teen TMA blocks were constructed with a manual tis-
sue microarrayer (Beecher Instruments, Sun Prairie, WI, 
USA), using 2 cores per tumor, each 1.5 mm in diameter, 
along with orientation and IHC control sample cores. 
For cases with low tumor tissue availability, inclusion of 
tumor tissue in TMAs was prioritized over DNA/RNA 
extraction. Thus, all 229 tumors were included in TMAs, 
while RNA was prepared from 207 tumors and DNA 
from 182. TCC was ≥30 % in 93 % of these cases.
IHC
Except for the above mentioned ER, PgR and HER2, 
Ki67 (clone MIB-1, Dako, Glostrup, DK), p-mTORSer2448 
(clone 49F9, CST, Danvers, MA, USA) and PTEN (clone 
6H2.1, Dako) were also examined with IHC, as previously 
described [23–25]. Ki67 classification as high (≥14  %) 
and low (<14 %) was applied for distinguishing the cen-
trally evaluated HER2-negative tumors as Luminal A and 
B [24]. PTEN protein expression (cytoplasmic, nuclear 
or both) was evaluated according to a staining intensity 
scale from 0 (negative, no staining) to 3 (intense stain-
ing). Tumors with PTEN IHC scores of 0 or 1 were con-
sidered to have PTEN loss. The phosphorylated form of 
mTOR at Ser2448, was defined as positive if at least mild 
cytoplasmic staining was detected in >1 % of tumor cells. 
In addition, c-Myc protein expression was assessed with 
a monoclonal antibody (clone 9E10, Dako, 1:300 dilu-
tion). For c-Myc protein, immunoreactive score (IRS) 
was calculated based on the intensity of positive stain-
ing and number of stained cells. Intensity scores of 0 
(no staining), 1 (mild), 2 (moderate), 3 (high intensity) 
and percentage scores were assigned as 1  =  1–25  %; 
2 = 26–50 %; 3 = 51–75 %; and 4 = 76–100 %. The IRS 
score ranged from 0 to 12 and classified tumors into four 
categories for negative (score 0–1); low (2–3); intermedi-
ate (4–5); and high (6–12) c-Myc protein expression.
The evaluation of all IHC was conducted by experi-
enced breast cancer pathologists (I.K. and M.B.), blinded 
as to the patients’ clinical characteristics and survival 
data.
FISH
FISH for the investigation of MET and MYC gene sta-
tus was performed with the ZytoLight SPEC MET/
CEN7 (Z-2087-200, ZytoVision Bremerhaven, Ger-
many) and LSI CMYC SpectrumOrange-labeled probe 
combined with CEP8 SpectrumGreen-labeled probe 
(both from Abbott Molecular, Abbott Park, IL, USA). 
CEP8 detects the centromeric region of the correspond-
ing chromosome, hence it will be called CEN8 for uni-
formity. The method was performed according to the 
manufacturer’s protocol with minor modifications. Sixty 
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non-overlapping nuclei from the invasive front of the 
tumor were randomly selected, according to morpho-
logical criteria using DAPI staining, and scored (E.T and 
M.B) for both green (MET and CEP8) and orange (MYC 
and CEN7) signals. For all probes, sequential (5 or more 
planes at 0.85–1.0 μm) digital images were captured using 
the Plan Apo VC 9100/1.40 objective (Nikon, Kanagawa, 
Japan) using specific filters for each probe. The resulting 
images were reconstructed using specifically developed 
software for cytogenetics (XCyto-Gen, Alphelys, Plaisir, 
France). Normal breast tissue specimens (n =  20) were 
used as a control of the FISH assays. All primary image 
data of the TMA and whole tumor sections have been 





ZUMAB, for MET and MYC, respectively.
MET amplification with FISH was defined as MET/
CEN7 ratio  ≥2.0 and/or  ≥4 average MET copies per 
nucleus. MYC amplification was defined as MYC/CEP8 
ratio ≥2.0 [26] and as MYC/CEN8 ratio ≥2.2 and/or ≥5 
copies per nucleus [27]. Except for MET and MYC, 
TOP2A gene status data as obtained with the triple assay 
used for HER2 gene assessment were also used with aver-
age ratio TOP2A/CEN17 ratio  ≥2.0 and/or  >4 TOP2A 
gene copies per nucleus as cut-off for amplification [28].
In addition, “polysomy” was investigated for all 
assessed chromosomes in the FISH assays, by classifying 
the number of observed centromere signals (CEN17 with 
the triplex assay; CEN7 for MET and CEP8 for MYC) 
based on counts in normal nuclei. Clearly, because only 
the centromeres and the specific gene loci were assessed 
per chromosome, observation of  >2 centromere signals 
does not necessarily correspond to chromosome poly-
somy or altered ploidy. Thus, we refer to increased CEN 
copies for this condition throughout the manuscript. 
Cut-offs for increased CEN copies were assessed on 20 
normal breast specimens and were calculated as normal 
mean CEN signal counts plus 3XSD, as previously sug-
gested [29]. Thus, increased CEN17 copies were called 
for >3.22; CEN7 for >3.36; and CEN8 for >3.13 mean sig-
nal counts per tumor.
DNA analyses for PIK3CA mutations and MET and MYC 
copy numbers
Mutation testing for hotspot PIK3CA mutations E542K 
and E545K (coding exon 9) and H1047R (coding exon 20) 
was accomplished with custom Taqman-MGB-SNP gen-
otyping assays (duplex qPCR for the detection of control 
DNA and mutant target in the same reaction, as previ-
ously described [22].
Copy number (CN) analysis for the MET and MYC 
genes was implemented with real time PCR (qPCR) 
in 180 DNA samples, with premade CNV assays (Life 
Technologies/Applied Biosystems, Paisley, UK). For 
each gene, two genomic regions were targeted in order 
to increase analysis specificity and sensitivity. Assay ID, 
Genbank reference, location within gene and amplicon 
size for the genes analyzed were: MET on chromosome 
7q31 (Hs02633538_cn; NM_000245.2, NM_001127500.1; 
exon 8; 80  bp/Hs05005398_cn; NM_000245.2, 
NM_001127500.1; intron 9; 107 bp); and MYC on chro-
mosome 8q24.21 (Hs00834648_cn; NM_002467.4; 
exon 2; 106  bp/Hs00292858_cn; NM_002467.4; exon 
3; 112  bp). The method involves duplex reactions, for 
the target gene, TaqMan® minor groove binding (MGB) 
probes, FAM™ labeled; for the reference gene, Taqman 
VIC®-TAMRA™ labeled probes, both assays with unlim-
ited primers. TaqMan® copy number reference assay 
RNase P was used as endogenous reference. Reactions 
(10 μl) were run in quadruplicates in an ABI7900HT sys-
tem in 384-well plates under default conditions. Three 
peripheral blood DNA samples from non-cancer patients 
were included in each run as calibrator samples, along 
with no-template controls (NTC). Results were obtained 
automatically with the CopyCaller™ Software v2.0 as 
predicted CN, in comparison to averaged calibrator val-
ues upon setting the evaluation threshold at Cp (crossing 
point)  =  32 for the reference RNaseP in each reaction. 
The ΔΔCT method was employed to estimate the CT dif-
ference (ΔCT) between target and reference sequence in 
tumor samples as compared to the corresponding values 
of the calibrator samples. Based on the Cp = 32 eligibil-
ity cut-off, out of 180 samples, 158 were informative for 
MET and 168 for MYC copy number assessment (87.8 
and 93.3 %, respectively).
MET and MYC CN were classified as no-gain for 
quadruplicate average CN ≤ 2.5 and as gain for average 
CN > 2.5. The cut-off 2.5 was chosen arbitrarily in order 
to exclude DNA replication. Both assays per gene had to 
be informative for the tumor evaluation. In cases with 
discrepant results between the two assays (no-gain and 
gain for the same tumor), gain was called for that particu-
lar gene.
Relative MET and MYC gene expression
cDNA synthesis was applied on the 207 RNA sam-
ples described above, with random primers and Super-
Script® III Reverse Transcriptase (Invitrogen™, Paisley, 
UK; cat. no. 48190011 and 18080044, respectively), 
according to the manufacturer’s instructions. cDNAs 
were assessed in duplicate 10  μl reactions in 384-well 
plates with qPCR in an ABI7900HT system for 45 cycles 
of amplification (default conditions). The following 
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exon-spanning premade Taqman-MGB assays (Applied 
Biosystems/Life Technologies) were selected for the 
transcripts under investigation (data in parentheses 
refer to assay ID; Genbank reference; amplicon loca-
tion; size): MET (Hs00179845_m1; NM_001127500.1, 
NM_000245.2; exons 10–11; 81 bp); MYC (Hs00153408_
m1; NM_002467.4; exons 2–3; 107 bp). A Taqman-MGB 
expression assay targeting β-glucuronidase (GUSB) 
mRNA (Hs00939627_m1; NM_000181.3; exons 8–9; 
96  bp) was used for the assessment of relative quantifi-
cation. GUSB was selected as the endogenous reference 
since, among the widely used housekeeping genes, it does 
not seem to be represented in pseudogenes. In addition, 
GUSB has been independently identified as one among 
the best preserved mRNA targets in FFPE tissues [30, 
31]. A commercially available reference RNA derived 
from multiple transformed cell lines (TaqMan® Control 
Total RNA, cat. no 4307281, Applied Biosystems) was 
applied in multiple positions in each run as positive con-
trol and for inter-run evaluation of PCR assay efficiency. 
To obtain linear Relative Quantification (RQ) values, 
relative expression was assessed as (40-dCT), whereby 
dCT (or delta Cycle Threshold, equivalent to Cq in MIQE 
guidelines) was calculated as (average target CT)—(aver-
age GUSB CT) from all eligible measurements under the 
sane reading threshold. Samples were considered eligible 
for GUSB CT  <36 and deltaRQ for each duplicate pair 
(intra-run variation) of <0.8. Inter-run RQ values for the 
reference RNA were  <1 for both assays. By using these 
criteria, 104 tumor samples were informative for MET 
and 140 for MYC relative mRNA expression.
Statistical analysis
All examined biomarkers are presented as category fre-
quencies and corresponding percentages, while asso-
ciations with HER2 status were examined using the Chi 
square or Fisher’s exact tests, where appropriate. For con-
tinuous mRNA RQ values the median was used for clas-
sifying low vs. high expression. Comparisons between 
MET and MYC FISH and qPCR CN were performed 
by calculating the Cohen’s Kappa measure of agree-
ment. Binary variable clustering was also performed 
for: CEN17/CEN7/CEN8 polysomy as 0, 1 and  >1, 
corresponding to the number of chromosomes with 
alterations.
Central IHC/FISH typing for the 229 available tumors 
revealed 139 HER2-positive and 90 HER2-negative cases. 
The rate of discordance (39.7 %) between local and cen-
tral typing was excessively high and appears to be due: to 
the different criteria used and the experience of patholo-
gists over 13  years in calling HER2-positive tumors; to 
pre-analytical and analytical conditions of the methods; 
and, also, to tumor heterogeneity with respect to HER2 
over-expression/amplification status [32, 33]. HER2 het-
erogeneity should definitely be considered as an issue for 
the observed discrepancy in this study, although unpre-
dictable, since the retrospective identification of different 
tumor blocks that were used for local and central test-
ing was impossible. In order to cover the HER2 status 
discrepancy, all parameters were analyzed in the entire 
cohort and separately in the centrally labelled HER2-
positive and negative groups. Table  1 includes selected 
demographic and tumor characteristics in the entire 
cohort.
Data on selected patient and tumor characteristics, 
previous and subsequent lines of treatment, disease pro-
gression events and survival were obtained from medical 
records and were entered into a central database. Fol-
low-up information for all patients was updated in July 
2015. Since not all patients had metastatic disease upon 
first diagnosis, the cohort was divided into two groups: 
(a) patients who presented with relapse from previously 
treated disease (R-mBC); and (b) patients who presented 
with metastatic breast cancer as first diagnosis (de novo 
mBC).
Patients received T in the 1st line of chemotherapy for 
metastatic disease and follow-up was updated in June 
2015. Time to progression (TTP) was defined as the 
time from T-treatment initiation in the 1st line treat-
ment (with or without concurrent chemo/hormonal 
therapy) to the date of documented disease progression. 
Survival was measured from initiation of T-treatment in 
the patients receiving the drug as a 1st line treatment to 
the date of death. Patients alive were censored at the date 
of the last follow-up contact. Survival probabilities were 
estimated by the Kaplan–Meier method. For the univari-
ate and multivariate analyses, Cox proportional hazards 
models were used. Univariate analyses were performed in 
the centrally identified HER2-positive and HER2-nega-
tive groups and, in the R-mBC and de novo mBC disease 
groups.
All tests were two-sided at a  =  0.05 level of signifi-
cance. No adjustment for multiple comparisons was 
performed. Multivariate analysis was performed in the 
entire cohort adjusted for HER2 status. Model choice 
was performed using backward selection with a removal 
criterion  =  0.15, including in the initial step clinical 
parameters such as: age, menopausal status, perfor-
mance status, receptor status (ER/PgR), Ki67 continu-
ous expression, number of metastatic sites, presentation 
of distant metastasis, presentation of disease (R-mBC vs. 
de novo-mBC) and HER2-status. The statistical analysis 
complied with the reporting recommendations for tumor 
marker prognostic studies (REMARK) [34] and was per-
formed using the SAS software (SAS for Windows, ver-
sion 9.3, SAS Institute Inc., Cary, NC, USA). The number 
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of informative cases along with all markers and applied 
methods are shown in Fig. 1.
Results
Association of markers with HER2 status and subtypes
Clinicopathological characteristics were similar in cen-
tral HER2-positive vs. HER2-negative tumors (Table  1) 
and in tumors from patients with R-mBC vs. de novo-
mBC (Additional file  1: Table S1) except for age and 
for the number of metastatic sites according to disease 
presentation.
In the entire cohort, 31 and 4 tumors were called MYC 
and MET amplified with FISH, respectively. Repre-
sentative examples are shown in Fig.  2. In comparison, 
15 and 40 tumors had MYC and MET copy gains with 
qPCR, respectively. Conceivably, low concordance was 
noticed for MYC status with qPCR and FISH (Kappa 
0.458 for qPCR vs FISH ratio; Kappa 0.416 for qPCR vs. 
Table 1 Patient characteristics in the entire cohort and according to central HER2 status
CT chemotherapy, RT radiotherapy
Significant p values are shown in italics
Entire cohort HER2-negative HER2-positive p value
N (%) 229 90 (39.3 %) 139 (60.7 %)
Age (years)
 Median (range) 57 (28–95) 59 (32–79) 55 (28–95) 0.035
N % N % N % p value
Menopausal status
 Pre 71 31 28 31.1 43 30.9 0.98
 Post 158 69 62 68.9 96 69.1
Performance status (N = 225)
 0 164 72.9 63 70.8 101 74.3 0.38
 1 47 20.9 18 20.2 29 21.3
 2–3 14 6.2 8 9 6 4.4
History (N patients with available data)
 Adjuvant CT (N = 228) 133 58.3 55 61.8 78 56.1 0.40
 Adjuvant CT anthracycline (N = 227) 90 39.6 29 33 61 43.9 0.10
 Adjuvant CT taxanes (N = 227) 55 24.2 17 19.3 38 27.3 0.17
 Adjuvant RT (N = 224) 87 38.8 35 39.8 52 38.2 0.82
 Adjuvant HT (N = 227) 108 47.6 45 51.1 63 46.3 0.48
Line of treatment
 1st line 192 83.8 68 75.6 124 89.2
 2nd line 31 13.5 18 20.0 13 9.4
 3rd line 2 0.9 2 2.2 0 0.0
 4th line 2 0.9 1 1.1 1 0.7
 5th line 1 0.4 0 0.0 1 0.7
 6th line 0 0.0 0 0.0 0 0.0
 7th line 1 0.4 1 1.1 0 0.0
Histological grade (N = 214)
 I–II 94 43.9 40 47.6 54 41.5 0.38
 III 120 56.1 44 52.4 76 58.5
Metastatic sites
 Locoregional 73 31.9 28 31.1 45 32.4 0.84
 Distant 203 88.6 83 92.2 120 86.3 0.17
 Bones 98 42.8 41 45.6 57 41.3 0.53
 Visceral 155 67.7 60 66.7 95 68.3 0.79
Number of metastatic sites
 <3 166 72.4 65 72.2 101 72.7 0.87
 ≥3 63 27.6 25 27.8 38 27.3
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FISH copies), while no concordance was revealed for 
MET, respectively. Similarly, no association was noticed 
between MET and MYC gene status and mRNA expres-
sion levels (high/low at any percentile) and c-Myc protein 
expression according to MYC gene status. c-Myc protein 
expression was more often absent or nuclear in centrally 
assessed HER2-positive as compared to negative tumors 
(Table 2), and so was high MET and MYC mRNA expres-
sion. The 4 cases with MET amplification, as assessed 
with FISH, and the majority of MYC amplified tumors 
were also HER2-positive. MET and MYC CN status by 
qPCR did not differ between HER2-negative and positive 
tumors. 
In comparison to centrally HER2-negative tumors 
(Table  2), centrally HER2-positive tumors were more 
often hormone receptor negative but positive for PTEN 
protein expression; at the genomic level, absence of 
PIK3CA mutations but presence of TOP2A amplification 
were also more common in these tumors. Ki67 labelling 
and p-mTOR protein expression did not differ between 
HER2-negative and positive tumors. PI3  K activation, 
reflected by PIK3CA mutations, PTEN protein absence 
and p-mTOR positivity, was observed in 197 (92.9  %) 
cases, 78 (95.1 %) being HER2-negative and 119 (91.5 %) 
HER2-positive patients.
The 139 centrally HER2-positive tumors were fur-
ther examined as Luminal-HER2 and HER2-Enriched 
(Additional file 1: Table S2), based on hormone receptor 
presence and absence, respectively. High MET mRNA 
was more often encountered in HER2-Enriched tumors; 
all other markers did not differ between these two sub-
types. Similarly, all markers examined were equally rep-
resented in R-mBC and de novo mBC (Additional file 1: 
Table S3).
Tumors with MYC amplification (FISH) or gain (qPCR 
CN) more frequently had nodal metastases (e.g., 8/14 
tumors (57 %) with MYC gain vs. 27/110 (19 %) with no 
gain had positive nodes; p =  0.002), while tumors with 
normal MET more often had visceral metastases (53  % 
with qPCR MET CN gain vs. 78  % with normal MET; 
p = 0.004).
Finally, as described above, the status of chromosome 
7, 8 and 17 centromeric regions was inferred from the 
centromere signal counts (CEN) in the FISH assays. A 
higher than normal copy number of CEN8 was associ-
ated with higher Ki67, as compared to tumors with nor-
mal CEN8 (Ki67 labelling mean ± SD of 57.6 ± 20.0 vs. 
38.3  ±  20.2, respectively; Mann–Whitney, p  <  0.001). 
CEN7 and CEN17 copies were not associated with any 
of the examined markers. Except for increased CEN17 
copies that were associated with TOP2A amplification 
(p  =  0.006), aberrant CEN7 and CEN8 copies did not 
respectively coincide with MET and MYC amplification 
or copy gain.
Association of markers with clinical outcome
Median follow-up for all 1st line treated patients 
was 109.6, 107.8  months in the HER2-negative and 
118.0  months in the HER2-positive group. The median 
TTP of the entire population was 14.5  months (95  % 
CI 11.7–17.8), 13.7  months (95  % CI 8.9–16.3) in the 
HER2-negative and 16.2  months (95  % CI 12.6–21.5) 
in the HER2-positive group. Of the 192 1st line treated 
patients, 146 (76.0  %) died. The median overall survival 
was 42.4  months (95  % CI 36.9–50.7). HER2-positive 
patients had numerically longer survival than HER2-
negative patients (median survival 49.7 vs. 38.1 months, 
respectively, p = 0.14).
The prognostic significance of the examined markers 
upon univariate Cox analysis are shown in Additional 
file  1: Table S4 for the entire cohort. As mentioned, all 
mBC patients received trastuzumab, although 39  % of 
the tumors were found to be HER2-negative upon cen-
tral evaluation. However, the central HER2-status did not 
significantly affect prognosis in this trastuzumab-treated 
cohort (Fig.  3a, b). Among typical clinicopathological 
parameters, worse PS and increased number of meta-
static sites were associated with shorter survival, while 
PIK3CA mutations conferred shorter TTP. Increased 
MYC CN, as assessed by qPCR but not by FISH, was 
associated with increased risk for disease progression 
Fig. 1 Remark diagram for the biological material tested
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and death (Fig. 3c, d); increased CEN8 copies were also 
unfavourable for survival. By contrast, decreased risk for 
disease progression and death was conferred by PgR and 
PTEN protein expression and p-mTOR positivity, and 
also by TOP2A gene amplification. MET CN by qPCR 
(Fig. 3e, f ) or by FISH, as well as CEN7 and CEN17 aber-
rations as single markers did not affect patient outcome.
When the cohort was split into central HER2-negative 
and HER2-positive, the majority of the above mark-
ers maintained their prognostic significance for survival 
(Additional file  1: Table S5) and TTP (Additional file  1: 
Table S6) in the same direction, but mostly in either 
group, HER2-negative or HER2-positive. As an excep-
tion, MYC CN gain was unfavourable in both groups 
with respect to survival. Interestingly, MET CN gain was 
favourable in the HER2-negative group only, for both 
TTP and survival. MYC CN gain retained its unfavour-
able prognostic significance for survival (Additional 
file 1: Table S7) and TTP (Additional file 1: Table S8) in 
both R-mBC and de novo-mBC patients, while TOP2A 
amplification was favourable in the absence of increased 
CEN17 copies in the R-mBC patients only.
Profiling of aberrations in all three studied chromosome 
CEN revealed 100 tumors without any aberration, 54 with 
aberrant CEN probe signals in one, 14 in two and 2 in all 
three chromosomes. Increased CEN8 copies were identi-
fied in 48 tumors (Table 2) and were prevalent in the above 
CEN aberration profiles. For example, the group with 1 
aberrant CEN included 34 patients with CEN8, 15 with 
CEN17 and 5 with CEN7 increased copies. Interestingly, 
patients with no aberrations and patients with two or three 
aberrant chromosomes in their tumors clustered together 
with respect to outcome. Thus, when using CEN patterns 
as a binary variable, patients bearing tumors with 1 aber-
rant chromosome fared worse than those with no or with 
more than 1 such alterations, particularly with respect to 
survival in the entire cohort (HR 1.72, 95 % CI 1.16–2.54, 
Wald’s p = 0.007, log-rank p = 0.006). The effect of these 
CEN profiles seemed specific for patients with R-mBC (for 
TTP, HR 1.62, 95  % CI 1.02–2.57, Wald’s p =  0.040; for 
survival, HR 2.39, 95 % CI 1.50–3.80, p < 0.001) (Fig. 4a, 
b). The interaction between CEN profiles and disease 
presentation was significant for patient survival (interac-
tion p =  0.025; Additional file  1: Table S9); the presence 
Fig. 2 Examples of MYC and MET status by FISH. a Normal MYC; b amplified MYC; c normal MET; d one of four amplified MET tumors
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Table 2 Marker associations according to central HER2 status
HER2-negative HER2-positive p value
Ki67 (%)
 Median (range) 38 (1–90) 40 (1–90) 0.12
HER2 copies (FISH)
 Median (range) 2 (1–9) 13 (2–39) <0.001
 Mean (±SD) 3 (1) 14 (8)
HER2 ratio (FISH)
 Median (range) 1 (1–8) 5 (1–28) <0.001
 Mean (±SD) 1 (1) 7 (4)
CEN17
 Median (range) 2 (1–4) 2 (1–4) 0.006
 Mean (±SD) 2 (1) 2 (1)
CEN8
 Median (range) 3 (1–9) 2 (1–5) 0.80
 Mean (±SD) 3 (1) 3 (1)
CEN7
 Median (range) 2 (1–4) 2 (1–5) 0.50
 Mean (±SD) 2 (1) 2 (1)
N % N % p value
IHC, categorical
 ER (N = 229)
  Negative 16 17.8 60 43.2 <0.001
  Positive 74 82.2 79 56.8
 PgR (N = 229)
  Negative 32 35.6 89 64 <0.001
  Positive 58 64.4 50 36
 mTOR (N = 229)
  Negative 36 40 48 34.5 0.40
  Positive 54 60 91 65.5
 PTEN (N = 183)
  Negative (0–1) 47 65.3 55 49.5 0.036
  Positive (2–3) 25 34.7 56 50.5
 c-MYC (N = 188)
  Both negative 19 24.4 41 37.3 0.011
  Both positive 27 34.6 31 28.2
  Cytoplasmic only 28 35.9 22 20
  Nuclear only 4 5.1 16 14.5
Mutations
 PIK3CA (N = 176)
  WT 49 69 88 83.3 0.020
  Mutant 22 31 17 16.2
Gene CN by qPCR
 MET (N = 159)
  No gain 42 71.2 77 77 0.41
  Gain 17 28.8 23 23
 MYC (N = 159)
  No gain 54 90 90 90.9 0.85
  Gain 6 10 9 9.1
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of 1 aberrant chromosome was unfavourable for patients 
with R-mBC (HR 2.39, 95 % CI 1.50–3.80), but the same 
alteration was favourable among patients with de novo-
mBC (HR 0.49, 95  % CI 0.24–1.00). When stratifying 
patients for central HER2 positivity, 1 aberrant chromo-
some conferred worse prognosis as compared to all other 
CEN profiles. The effect seemed more specific for patients 
with centrally evaluated HER2-negative tumors; such 
patients bearing tumors with 1 aberrant chromosome had 
the worst outcome (for TTP, HR 3.08, 95 % CI 1.45–6.56, 
Wald’s p = 0.004; for survival, HR 3.60, 95 % CI 1.67–7.76, 
p  =  0.001) (Fig.  4c, d). The interaction between central 
HER2-status and CEN patterns (Additional file  1: Table 
S9) was significant for both disease progression and death 
(interaction p  =  0.041 and 0.079, respectively). Among 
patients with tumors with 1 aberrant chromosome, those 
with centrally HER2-positive fared better than those with 
HER2-negative tumors. This alteration was an unfavour-
able prognosticator for TTP in HER2-negative but not in 
HER2-positive tumors. No difference was observed for 
CEN profiles on patient outcome with respect to HER2 
subtypes (luminal and enriched).
Multivariate analysis for the parameters described was 
conducted in the entire cohort, in the central HER2-
positive and HER2-negative groups, as well as in the R- 
and de novo mBC patient groups (Table  3 for survival 
and Additional file 1: Table S10 for TTP). ER/PgR posi-
tivity was the most consistent independent favourable 
prognosticator in the entire cohort, and separately in 
R-mBC and in de novo mBC patients. MYC CN indepen-
dently predicted for worse TTP and survival in the entire 
cohort, in patients with centrally HER2-positive tumors 
Significant p values are shown in italics
Table 2 continued
N % N % p value
Gene status by FISH
 MET (N = 164)
  Non-amplified 56 100 104 96.3 0.15
  Amplified 4 3.7
 MYC (N = 173)
  Non-amplified 56 88.9 86 78.2 0.077
  Amplified 7 11.1 24 21.8
 TOP2A (N = 226)
  Non-amplified 82 93.2 74 53.6 <0.001
  Amplified 6 6.8 64 46.4
 CEN17 (N = 226)
  Normal 82 93.2 119 86.2 0.10
  Increased 6 6.8 19 13.8
 CEN7 (N = 170)
  Normal 54 90 101 91.8 0.69
  Increased 6 10 9 8.2
 CEN8 (N = 174)
  Normal 47 74.6 79 71.2 0.63
  Increased 16 25.4 32 28.8
 CEN profiles (N = 170)
  0 chromosomes 40 66.7 60 54.5 0.21
  1 chromosome 13 21.7 41 37.3
  2 chromosomes 6 10 8 7.3
  3 chromosomes 1 1.7 1 0.9
mRNA
 MET (N = 139)
  Low 36 63.2 36 43.9 0.025
  High (≥50th perc.) 21 36.8 46 56.1
 MYC (N = 140)
  Low 36 63.2 37 44.6 0.031
  High (≥50th perc.) 21 36.8 46 55.4
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and in patients with R-mBC. Further, in the entire cohort 
of patients treated with trastuzumab the interaction of 
CEN profiles with disease presentation was significant 
for survival, while the interaction with HER2 subtypes 
was significant for TTP. In this context, good patient 
performance status and TOP2A amplification also inde-
pendently predicted for longer survival. Central HER2 
positivity did not affect patient outcome.
Fig. 3 Patient outcome according to central HER2 status, MYC and MET copy numbers (CN). CN was assessed by qPCR. a, c, e survival; b, d, f time 
to progression
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The outcome of patients with centrally evaluated HER2-
negative tumors seemed significantly adversely affected by 
the absence of ER/PgR positivity, post-menopausal status, 
and by increased Ki67. In the group of 49 patients with 
de novo mBC, good performance status, ER/PgR positiv-
ity, and the HER2-Enriched subtype predicted for longer 
survival; in addition to these parameters, pre-menopausal 
status and MET amplification predicted for longer TTP. 
The statistically significant results obtained for MYC CN 
gain in this patient group, as well as for MYC amplifica-
tion with FISH in HER2-negative patients, concerned 
only four patients in each case and were not considered to 
be clinically significant. Of note though, the four patients 
with MYC amplification also had increased CEN8 CN.
Discussion
Discordant inter-laboratory HER2 status still represents 
an important issue in the clinic, even after more than 
10  years of practicing and extensive external quality 
assurance rounds for method standardization and guide-
line updates on this predictive marker. The overall local 
vs. central testing discordance rate varies between 2.5 
and 20 %, with HER2 heterogeneity and laboratory ana-
lytical and post-analytical issues as the major contribu-
tors to this discrepancy [32, 35–37]. More than twice 
as many discrepant cases are locally HER2-positive/
centrally HER2-negative. Although some of these cases 
may be “true false positives”, accurate HER2 testing still 
represents a challenge [32, 37]. All above parameters 
and the fact that patients were treated with trastuzumab 
in the early years of HER2 testing may have accounted 
for the high discordance rate observed in the examined 
series upon retrospective central assessment. Whether 
the locally positive/centrally negative tumors were “false 
positives” can by no means be resolved; such tumors had 
nevertheless mean HER2 copy number of 3, indicating 
low level aberrations of the HER2 amplicon that might 
have contributed to HER2 over-expression. Further, 
Fig. 4 Effect of centromere profiles on the outcome of patients with metastatic breast cancer (mBC). In a, b, patients were distinguished in those 
who relapsed after adjuvant treatment (R-mBC), and those who presented with metastatic disease at first diagnosis (de novo mBC). In c, d, patients 
were grouped for centrally HER2-positive and HER2-negative disease. a, c Survival; b, d time to progression. 1chr increased CEN copies in 1 chromo-
some only; other normal CEN or increased copies for >1 CEN
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patient outcome did not differ in the two groups. Hence, 
these tumors were considered to be of ambiguous HER2 
status, as opposed to “true positives” upon local and cen-
tral testing.
This study mainly focused on the effect of MYC and 
MET status on mBC patient outcome upon trastuzumab 
treatment and shows that MYC but not MET CN status 
adversely affected the outcome of mBC patients treated 
Table 3 Multivariate Cox regression analysis for patient survival
N number, CI confidence interval, CN copy number, italics unfavorable, bold italics favorable prediction
Entire cohort (N = 119) N of patients N of events Hazard ratio 95 % CI Wald’s p
 Performance status
  1–2–3 vs. 0 32 vs. 87 27 vs. 61 1.64 1.03–2.62 0.036
 TOP2A (FISH) ratio 2.0 copies 4.0
  Amplified vs. non-amplified 42 vs. 77 28 vs. 60 0.62 0.38–1.00 0.050
 MYC CN
  Gain vs. no gain 10 vs. 109 10 vs. 78 6.02 2.67–13.6 <0.001
 Type of disease*CEN profile (binary) 0.048
  CEN profile, 1chr vs. other @ R-mBC 28 vs. 58 24 vs. 39 2.29 1.36–3.85
  CEN profile, 1chr vs. other @ de novo-mBC 12 vs. 21 9 vs. 16 0.77 0.29–2.04
  de novo-mBC vs. R-mBC @ CEN profile, other 21 vs. 58 16 vs. 39 1.15 0.64–2.08
  de novo-mBC vs. R-mBC @ CEN profile, 1chr 12 vs. 28 9 vs. 24 0.39 0.16–0.93
HER2-positive (N = 83)
 TOP2A (FISH) ratio 2.0 copies 4.0
  Amplified vs. non-amplified 39 vs. 44 25 vs. 35 0.58 0.35–0.98 0.041
 MYC CN
  Gain vs. no gain 7 vs. 76 7 vs. 53 4.40 1.90–10.2 0.001
HER2-negative (N = 45)
 Menopausal status
  Post vs. pre 28 vs. 17 25 vs. 10 3.69 1.57–8.65 0.003
 ER/PgR
  Positive vs. negative 39 vs. 6 29 vs. 6 0.22 0.08–0.58 0.002
 MYC FISH binary (ratio 2, copies >5)
  Amplified vs. non-amplified 4 vs. 41 4 vs. 31 4.54 1.40–14.70 0.012
 Ki67 (by increase 5 %) 1.16 1.07–1.26 0.001
R-mBC (N = 84)
 Age
  ≥50 vs. <50 56 vs. 28 39 vs. 23 0.50 0.28–0.89 0.019
 Performance status
  1-2-3 vs. 0 25 vs. 59 22 vs. 40 1.83 1.07–3.14 0.028
 ER/PgR
  Positive vs. negative 57 vs. 27 39 vs. 23 0.43 0.24–0.76 0.004
 PI3K
  Activation vs. non-activation 74 vs. 10 56 vs. 6 4.50 1.63–12.39 0.004
 MYC CN
  Gain vs. no gain 6 vs. 78 6 vs. 56 20.48 6.77–61.99 <0.001
de novo-mBC (N = 49)
 Performance status
  1-2-3 vs. 0 13 vs. 36 12 vs. 26 1.99 0.99–4.02 0.055
 ER/PgR
  Positive vs. negative 36 vs. 13 27 vs. 11 0.16 0.03–0.77 0.023
 HER2 status/subtypes 0.13
  Luminal HER2 vs. HER2-negative 21 vs. 17 16 vs. 13 1.15 0.53–2.49 0.72
  HER-enriched vs. HER2-negative 11 vs. 17 9 vs. 13 0.20 0.04–0.96 0.045
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with trastuzumab. MYC and MET were assessed at mul-
tiple molecular levels, by multiple methods, all of which 
have intrinsic characteristics. At the gene level, FISH 
probes detect, although not exclusively, the gene of inter-
est on the corresponding chromosome, while CN assess-
ment with qPCR is gene specific but may suffer from 
PCR target efficiency and calibrator DNA characteristics; 
hence, the two methods do not always yield the same 
information on gene copy status [38]. By using the crite-
ria for MYC amplification provided by Perez et  al. [27], 
we recapitulated the findings of that study concerning the 
15 % incidence of MYC amplification without any prog-
nostic effect for this marker in HER2-positive patient, 
further supporting that co-amplified MYC and HER2 
confer poor prognosis in patients treated with anthracy-
clines but not with anti-HER2 targeted drugs [39].
The incidence of tumors with MYC CN gain, as 
assessed with qPCR CNV assays, was only half compared 
to FISH MYC amplification; out of these cases, only half 
were concordant with both methods. In the only study to 
our knowledge comparing the two methods, conducted 
on medulloblastomas for MYC genes including MYC on 
chromosome 8 [40], FISH would detect less MYC ampli-
fied cases than qPCR. The opposite was noticed here. 
This implies that in some of the cases with FISH ampli-
fication, different aberrations than simply multiple MYC 
copies may exist, e.g., gene rearrangements in 8q24.21, a 
locus involved in established translocations in hemato-
poetic malignancies. Further, MYC was investigated here 
for mRNA and protein expression. Other than described 
in angiosarcomas, breast included [41], MYC gene status 
by either method in this study did not predict for MYC 
mRNA and protein over-expression, in line with previ-
ous observations in breast carcinomas [14]. Thus, over-
all, the novel finding concerning MYC in this study was 
the strongly unfavourable prognostic effect of CN gain in 
mBC patients treated with trastuzumab. Of note, MYC 
CN gain as a marker may be a method-limited surro-
gate, additionally biased by the small number of patients 
carrying this alteration. However, survival of all these 
12 patients was shorter than the median observed for 
patients without MYC CN gain; thus, this marker may be 
considered for evaluation in larger series.
MET amplified calls with FISH and with qPCR practi-
cally hardly overlapped; tumors with MET CN gain by 
qPCR were ten times more than MET amplified tumors 
by FISH, while no association was observed between 
MET gene parameters and MET mRNA expression. 
Although the cut-off for FISH amplification was substan-
tially lower than the one recently proposed [42], the rate 
of MET amplified cases in the present series was very 
low and their number too small for meaningful statisti-
cal analyses. The discrepancy between FISH and qPCR 
MET status was probably due to the low copy number 
load even in tumors with MET CN gains, as previously 
discussed [38, 40]. Nevertheless, MET CN gain showed a 
trend as an independent unfavourable marker in patients 
who presented with de novo mBC, which might be con-
sidered as a surrogate for an adverse effect of MET CN 
aberrations in the present clinical context.
An important piece of data from this study corresponds 
to the effect of CEN copy patterns in patients with tras-
tuzumab treated mBC. Aberrant CEN copies under any 
name (polysomy, CEP-duplication, aneusomy) corre-
spond to genomic/chromosonal instability in breast can-
cer [43, 44], may explain equivocal HER2 status [45] and 
may be related to tumor proliferation [44]. Herein, of the 
three centromeres studied, only increased CEN8 copies 
were associated with tumor proliferation. However, CEN 
profiles had diverse impact on patient outcome, accord-
ing to HER2 status and presentation of disease, confer-
ring opposite prognosis in patients with ambiguous 
HER2 as compared to true positives, as well as in patients 
with R-mBC as compared to de novo mBC. Importantly, 
normal or complex CEN gains had the same but oppo-
site impact on prognosis as compared to single CEN 
gains, indicating that the extent of instability and not the 
chromosome target per se affects patient outcome. Chro-
mosomal instability has so far been related to adjuvant 
anthracycline efficiency in breast cancer [43, 46]. The 
present study may be the first one to show a prognos-
tic effect of chromosomal instability in the mBC setting 
involving trastuzumab treatment. This finding is impor-
tant since it concerns about one-third of mBC patients 
treated with this drug, and mostly those with ambiguous 
HER2 status. However, whether the observed prognostic 
CEN profile effect is related to trastuzumab or to chemo-
therapy treatments that were also administered to these 
patients needs to be evaluated in appropriately designed 
prospective studies.
In addition, Ki67 labelling in a continuous mode 
reflecting tumor proliferation rate, and PI3K activa-
tion had distinct prognostic effects in mBC patient sub-
sets in the present study. Tumor proliferation emerged 
as an independent poor prognosticator in patients with 
R-mBC but not with de novo mBC and in patients with 
ambiguous HER2 but not with true positive HER2 status. 
The latter may be related to the effect of increased CEN 
copies in the ambiguous HER2 group, linking prolifera-
tion with chromosomal instability, as previously reported 
[44]. Ambiguous and true HER2-positive tumors mainly 
differed in hormone receptor positivity and, probably 
because of that, in the incidence of PIK3CA mutations 
and PTEN loss. The latter were, as expected [47], more 
frequent in tumors with ambiguous HER2 status, which 
were also more frequently ER/PgR-positive. However, 
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the presence of hormone receptors was the independ-
ent prognosis-relevant factor in both ambiguous and 
true HER2-positive patients. When examined separately, 
PIK3CA mutations, PTEN loss and mTOR activation 
were outcome-related in subsets of patients, but were 
not retained in multivariable models. However, all three 
parameters in combination, indicative of PI3K activation, 
were independently associated with poor prognosis in 
patients with R-mBC only. Although this finding may be 
biased by the small number of patients without PI3K acti-
vation in the present cohort, it appears to be in accord-
ance with PI3K activation as a cause for trastuzumab 
resistance [48] and it also highlights the differences in 
disease biology in patients treated before the manifesta-
tion of metastases, as compared to those who present 
with metastatic disease at first diagnosis. Of note, pri-
mary tumors were examined in all cases of this study, but 
PI3K activation in those with de novo mBC did not seem 
to affect patient outcome. This may be important when 
considering PI3K inhibition as a therapeutic adjunct in 
mBC patients.
Conclusions
The present study highlights the potential clinical rel-
evance of MYC copy number status, PI3K activation and 
chromosomal instability in patients with mBC treated 
with trastuzumab for HER2-positive disease. These 
markers may have distinct impact on patient outcome 
according to solid or ambiguous positive HER2 status of 
the tumors, and to metastasis manifestation. Limitations 
of the study are its retrospective nature and the small 
size of the emerged patient subgroups with significant 
marker implications. If validated in studies with adequate 
statistical power, especially with regards to R-mBC and 
de novo mBC, the herein presented markers may prove 
important for the therapeutic assessment of patients with 
HER2-positive metastatic disease.
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